Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 185,011 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Prostate Cancer
Interventions: dolastatin 10; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 3
States / cities: Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Pain
Interventions: ALGRX 3268; Drug
Lead sponsor: AlgoRx Pharmaceuticals; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 101
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 77 more

Conditions: Prostate Cancer
Interventions: atrasentan hydrochloride; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Thoracoabdominal Aneurysms
Interventions: Visceral Manifold and Thoracic Bifurcation, Unitary Manifold; Device
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Healthy, no Evidence of Disease, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: light-scattering spectroscopy; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Breast Tumors, Breast Neoplasms
Interventions: Decitabine, LBH589, Tamoxifen; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Atrial Fibrillation, Prescribing Practices, Anticoagulants
Interventions: Anticoagulation (AC) Intervention--Academic Detailing, Anticoagulation (AC) Intervention--Prescribing Practices; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Acne
Interventions: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel, Vehicle Gel; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: San Diego, California • Denver, Colorado • Longmont, Colorado + 24 more

Conditions: Ulcerative Colitis
Interventions: Given® Diagnostic System; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Defect, Congenital
Interventions: Xeltis Bioabsorbable Pulmonary Valved Conduit; Device
Lead sponsor: Xeltis; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Hollywood, Florida + 4 more

Conditions: Hyperuricemia, Gout, Qt Interval, Variation in
Interventions: LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Resistant Solid Malignancies
Interventions: Temsirolimus, Docetaxel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Urologic Neoplasm
Interventions: Cetuximab, Paclitaxel; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Hospitalization; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions: amifostine trihydrate, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 4
States / cities: Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more

Conditions: PTSD, Acupuncture, Combat
Interventions: Acupuncture; Device
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Overweight, Obesity
Interventions: Reduced calorie diet and exercise plan, Different reduced calorie diet and exercise plan; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Health-related Quality of Life
Interventions: Vitality Product, Placebo; Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Tucson, Arizona • Chaska, Minnesota • Houston, Texas

Conditions: Cervical Degenerative Disc Disease
Interventions: Anterior Cervical Discectomy and Fusion; Device
Lead sponsor: Synergy Spine Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 23
States / cities: Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 20 more

Conditions: Bacterial Infections
Interventions: Likmez® (metronidazole) Oral Suspension; Drug
Lead sponsor: Saptalis Pharmaceuticals LLC; Industry
Eligibility: 12 Months to 4 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Miami, Florida • Richmond, Texas

Conditions: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Epanova® (omega-3 carboxylic acids), corn oil control; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 229
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Michael O'Connor; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Disease, Mental Health, Caridovascular Disease, Stress, Adolescent Health
Interventions: Tools for Arctic Health Promotion; Behavioral
Lead sponsor: University of Alaska Fairbanks; Other
Eligibility: 12 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fairbanks, Alaska

Search by objective public record fields.

Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

Atrasentan in Treating Patients With Prostate Cancer

Visceral Manifold and Unitary Device Study for the Repair of Thoracoabdominal Aortic Aneurysms

Light-Scattering Spectroscopy for Detection of Breast Cancer

Re-expression of ER in Triple Negative Breast Cancers

Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

Wireless Capsule Endoscopy in Ulcerative Colitis

Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Psychosocial Syndemics of Heart Failure

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Acupuncture for Post-Traumatic Stress in Combat Veterans

Association Between the Menstrual Cycle and Weight Loss

Effects of a Vitality Dietary Supplement on Physical and Mental Function in Middle-aged Adults

The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Detection of Aggressive Breast Tumors Using Tc-99m-NC100692

Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health